Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AGL Stock Forecast 2026-2027
$111.79
Current Price
$1.87B
Market Cap
Buy 4
Hold 11
Sell 2
Wall St Analyst Ratings
Distance to AGL Price Targets
+7.3%
To High Target of $120.00
-37.8%
To Median Target of $69.50
-80.3%
To Low Target of $22.00
AGL Price Momentum
+0.7%
1 Week Change
+9.4%
1 Month Change
+95.3%
1 Year Change
+548.8%
Year-to-Date Change
-11.1%
From 52W High of $125.71
+1,394.5%
From 52W Low of $7.48
📊 TOP ANALYST CALLS
Did AGL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Agilon Health is one of their latest high-conviction picks.
Latest AGL Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, AGL has a neutral consensus with a median price target of $69.50 (ranging from $22.00 to $120.00). The overall analyst rating is Buy (6.7/10). Currently trading at $111.79, the median forecast implies a -37.8% downside. This outlook is supported by 4 Buy, 11 Hold, and 2 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AGL Analyst Ratings
4
Buy
11
Hold
2
Sell
AGL Price Target Range
Low
$22.00
Average
$69.50
High
$120.00
Current: $111.79
Latest AGL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AGL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 26, 2026 | Barclays | Andrew Mok | Equal-Weight | Upgrade | $81.00 |
| May 21, 2026 | Benchmark | Bill Sutherland | Buy | Maintains | $95.00 |
| May 15, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| May 11, 2026 | TD Cowen | Hold | Maintains | $N/A | |
| May 8, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| May 7, 2026 | Evercore ISI Group | In-Line | Maintains | $N/A | |
| May 7, 2026 | Jefferies | Buy | Upgrade | $N/A | |
| May 7, 2026 | Baird | Neutral | Maintains | $N/A | |
| May 7, 2026 | Deutsche Bank | Buy | Upgrade | $N/A | |
| May 4, 2026 | JP Morgan | Underweight | Downgrade | $N/A | |
| Apr 2, 2026 | Benchmark | Buy | Maintains | $N/A | |
| Mar 3, 2026 | Citigroup | Neutral | Maintains | $N/A | |
| Feb 27, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Feb 27, 2026 | Barclays | Underweight | Maintains | $N/A | |
| Nov 6, 2025 | Barclays | Underweight | Maintains | $N/A | |
| Nov 5, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Oct 7, 2025 | Wells Fargo | Overweight | Maintains | $N/A | |
| Aug 20, 2025 | Bernstein | Market Perform | Downgrade | $N/A | |
| Aug 15, 2025 | Jefferies | Hold | Maintains | $N/A | |
| Aug 14, 2025 | Baird | Neutral | Maintains | $N/A |
agilon health, inc. (AGL) Competitors
The following stocks are similar to Agilon Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
agilon health, inc. (AGL) Financial Data
agilon health, inc. has a market capitalization of $1.87B with a P/E ratio of -4.8x. The company generates $5.82B in trailing twelve-month revenue with a -6.1% profit margin.
Revenue growth is -7.3% quarter-over-quarter, while maintaining an operating margin of +0.7% and return on equity of -109.6%.
Valuation Metrics
Market Cap
$1.87B
Enterprise Value
$1.67B
P/E Ratio
-4.8x
PEG Ratio
0.0x
Price/Sales
0.3x
Growth & Margins
Revenue Growth (YoY)
-7.3%
Gross Margin
+4.6%
Operating Margin
+0.7%
Net Margin
-6.1%
EPS Growth
+303.9%
Financial Health
Cash/Price Ratio
+12.4%
Current Ratio
1.0x
Debt/Equity
18.4x
ROE
-109.6%
ROA
-14.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
agilon health, inc. (AGL) Business Model
About agilon health, inc.
What They Do
Transforms senior care through physician partnerships.
Business Model
The company operates a Medicare-centric platform that employs a subscription-like model, charging per-member-per-month fees. This approach allows physicians to manage the total healthcare needs of their patients while shifting from a fee-for-service to a value-based care system. By providing integrated technology and operational support, Agilon Health enhances care coordination and optimizes patient outcomes.
Additional Information
Founded in 2016 and based in Westerville, Ohio, Agilon Health currently operates in 12 states. The company supports Medicare Advantage members and participants in the ACO REACH model, promoting physician independence and collaboration for improved healthcare delivery.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
856
CEO
Mr. Timothy Patrick O'Rourke
Country
United States
IPO Year
2021
Website
www.agilonhealth.comagilon health, inc. (AGL) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
What's Making Tenet Healthcare Stock Stand Out Right Now?
THC is gaining on rising admissions, strong ambulatory care growth and earnings momentum. But can it sustain gains as expenses keep climbing?
Jul 06, 2026
By Zacks Equity Research
Analyst Blog
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.
Jul 03, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Agilon (AGL) has shown strong momentum recently and is considered a reasonable investment choice, passing the 'Fast-Paced Momentum at a Bargain' screening criteria.
Why It Matters
Agilon (AGL) shows strong recent momentum and remains reasonably priced, making it an attractive opportunity for value-focused investors seeking growth.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Agilon Health (AGL) is being evaluated for its potential as a top stock pick for momentum investors. Further analysis is needed to assess its suitability.
Why It Matters
Agilon Health's potential as a momentum stock may indicate growth opportunities, impacting its stock performance and attracting investor interest in a competitive market.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Agilon Health is rated Buy with a $177 price target after a strong Q1 2026, posting $1.42B revenue and $54M adjusted EBITDA. Full-year guidance raised due to margin expansion and operational improvements.
Why It Matters
Agilon Health's strong Q1 results and raised guidance signal robust growth and operational efficiency, indicating potential for significant stock appreciation and a solid investment opportunity.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
AGL stock is experiencing notable activity in the options market, signaling potential investment opportunities for investors to monitor closely.
Why It Matters
Increased activity in AGL's options market suggests heightened investor interest or volatility, potentially indicating significant upcoming price movements or changes in sentiment.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Agilon Health, Inc. (NYSE: AGL) will participate in investor meetings and an ACO Model panel at the Truist Securities Healthcare Disruptors & Digital Health Conference on June 23, 2026.
Why It Matters
Agilon Health's participation in key industry conferences highlights its strategic focus and potential growth in healthcare transformation, signaling opportunities for investors in the evolving market.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Investors may find potential top stock performers of 2026 already included in their small-cap ETFs.
Why It Matters
Small-cap ETFs may hold high-potential stocks poised for significant growth, highlighting opportunities for current investors to capitalize on future gains without additional purchases.
Source: Benzinga
Market Sentiment:
Positive
Frequently Asked Questions About AGL Stock
What is agilon health, inc.'s (AGL) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, agilon health, inc. (AGL) has a median price target of $69.50. The highest price target is $120.00 and the lowest is $22.00.
Is AGL stock a good investment in 2027?
According to current analyst ratings, AGL has 4 Buy ratings, 11 Hold ratings, and 2 Sell ratings. The stock is currently trading at $111.79. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AGL stock?
Wall Street analysts predict AGL stock could reach $69.50 in the next 12 months. This represents a -37.8% decrease from the current price of $111.79. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is agilon health, inc.'s business model?
The company operates a Medicare-centric platform that employs a subscription-like model, charging per-member-per-month fees. This approach allows physicians to manage the total healthcare needs of their patients while shifting from a fee-for-service to a value-based care system. By providing integrated technology and operational support, Agilon Health enhances care coordination and optimizes patient outcomes.
What is the highest forecasted price for AGL agilon health, inc.?
The highest price target for AGL is $120.00 from at , which represents a 7.3% increase from the current price of $111.79.
What is the lowest forecasted price for AGL agilon health, inc.?
The lowest price target for AGL is $22.00 from at , which represents a -80.3% decrease from the current price of $111.79.
What is the overall AGL consensus from analysts for agilon health, inc.?
The overall analyst consensus for AGL is neutral. Out of 4 Wall Street analysts, 4 rate it as Buy, 11 as Hold, and 2 as Sell, with a median price target of $69.50.
How accurate are AGL stock price projections?
Stock price projections, including those for agilon health, inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 2:58 PM UTC